Home
This site is intended for healthcare professionals
Share

Description

This activity is supported by an independent education grant from BMS. This online education program has been designed for healthcare professionals globally, excluding the UK.

Join expert Toby Maher, MD, PhD, for a case-based clinical review on evaluating progressive pulmonary fibrosis (PPF). This session addresses the transition from diagnostic suspicion to actionable care plans, highlighting how structured radiology reporting and shared care decision frameworks eliminate communication gaps across specialties.

This is Module Two of Four. Modules One, Three, and Four can be found here.

Session Highlights

  • Utilize serial pulmonary function tests (PFTs) and HRCT imaging to objectively verify 2022 ATS/ERS/JRS/ALAT criteria for progressive pulmonary fibrosis.
  • Transition from narrative free-text radiology reports to structured template dashboards that feature automated pattern classifications and action triggers.
  • Integrate multidisciplinary team (MDT) consensus views across rheumatology, pulmonology, radiology, pathology, and nursing to refine diagnostic accuracy.
  • Operationalize a Shared Care Decision Tree with designated step owners to ensure seamless transition from PPF alerts to treatment initiation.

Target Audience

This activity is intended for pulmonologists, rheumatologists, thoracic radiologists, pathologists, pulmonology nurse practitioners, and physician assistants/associates who are central to the diagnosis and management of IPF and PPF. It is also designed for general practitioners, respiratory therapists, pharmacists, and other multidisciplinary healthcare professionals involved in the care of patients with pulmonary fibrosis.

Faculty

Dr Toby Maher is Professor of Clinical Medicine and Director of Interstitial Lung Disease at the Keck School of Medicine of the University of Southern California. He has dedicated his career to advancing clinical care, education, and research in interstitial lung disease, idiopathic pulmonary fibrosis, and progressive pulmonary fibrosis.

Disclosures

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Dr Toby Maher, faculty for this educational activity, has the following relevant financial relationships: Consultant, Advisor, and Speaker for AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chiesi, GSK, Insmed, Merck, and United Therapeutics.

The MedAll staff, program planners, and reviewers have no relevant financial relationships with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

Partners designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 ANCC contact hours.

Pharmacy Continuing Education

Partners designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number - JA4008073-9999-26-362-H01-P

Type of Activity: Knowledge

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

PA Continuing Medical Education

Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until September 30, 2027. PAs should only claim credit commensurate with the extent of their participation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hour(s). To successfully complete this activity and receive CE credit, learners must follow these steps during the period from 1 November 2026 through to 30 September 2027.

  1. Review the objectives and disclosures
  2. Study the educational content
  3. Successfully complete activity post-test(s)
  4. Complete the activity evaluation

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the online evaluation, your credit will be submitted to CPE Monitor. Please check your NABP account within thirty (30) days to make sure the credit has been posted.

This continuing education activity is active starting 1 November, 2026 and will expire on 30 September, 2027.

Estimated time to complete this activity: 15 Minutes

Learning objectives

By the end of this activity participants will be able to:

  • Incorporate risk stratification, high‑resolution imaging, and multidisciplinary assessment to differentiate and diagnose IPF and PPF from other ILDs early and accurately.

  • Implement multidisciplinary diagnostic and management strategies to improve timely recognition, referral, and coordinated care for patients with PF.

  • Apply knowledge of mechanisms of action and clinical evidence to treatment decisions, including patient selection and therapy timing.

Similar communities

View all

Similar events and on demand videos

Computer generated transcript

Warning!
The following transcript was generated automatically from the content and has not been checked or corrected manually.

Hello everybody, I'm Ted Maher. I'm director of the Interstitial Lung Disease Unit at the University of Southern California, Los Angeles. Great to be joining you for this conversation. So, at this point, uh, we're going to think about Margaret having been re-referred back to us. So we're 6 months later, uh she's come back, we have her diagnostic assessment. As you can see on the screen, her force survival capacity has declined from 82% predicted down to 74% predicted, uh, a drop of 8% points compared with 6 months previously. She's got a DLCO that now stands at 61% predicted. We have a CT scan that shows a probable UIP pattern and importantly, When the latest CT has been compared to her previous images, uh, there's an apparent increase in reticulation, uh, albeit there is no, uh, definite honeycombing at this stage. Uh, on her serology, uh, she has, uh, anti-CCP positivity, uh, and she is taking methotrexate for her joint disease. So just um to explore a scenario, uh, obviously, everybody listening to this is likely to have been part of an ILD MDT. Everybody will certainly have read reports from radiologists and tried to interpret them. On the left-hand side of the screen, we have what might be considered a traditional, uh, radiology report. You can see the free text says bilateral basal reticulation. Retraction bronchiectasis, no definite honeycombing, clinical correlation advised. And the question is, what do you do with that? Now, for those that are confident in managing ILD you may just go and look at the scan yourself and make your own structured interpretation. But for fellows or pulmonologists less uh comfortable with managing ILD. That sort of report is often difficult for them to interpret. And on the right-hand side, we have instead, uh, what might be considered a structured approach to reporting. And, and in this approach, the radiologist is using a template for an ILD report. Uh, and you can see here that it is broken down in a way that can then be interpreted and actioned on by the pulmonologist and the MDT meeting. So we have a pattern. Uh, this is defined as probable UIP according to the latest guidelines. There is the option um for a UIP confidence rating. Uh, there's then, uh, a specific bullet point, uh, asking for a comparison with previous imaging, so fibrosis extent versus prior. And on this occasion, uh, it has progressed. Uh, and then a trigger, is there something in this report that should flag this patient for discussion at the MDT? Uh, and in this case, because the fibrosis extent has progressed, there is a trigger, um, for MDT discussion of this patient. Uh, and I think if you just compare the, the right-hand report with the left-hand report, you can see that although there are probably fewer words used on the right-hand side, the quality of information contained in that report is a lot better, and it is a lot clearer what needs to happen for this patient going forward. Um, and as is stated in the bullet point at the bottom of the slide, NDT agreement between different centers is already very poor, and some of that comes down to different interpretation of the information available. Taking a structured approach is one way of trying to harmonize outcomes across NDTs and to ensure that patients are getting best care in a timely manner. So here we have an example of a, a dashboard that is available for providing a more structured approach um to MDT based thinking about patients. Uh, you can see on this dashboard, we have contained all of the critical information that we might need to take action in this case. So if we go from the top left-hand corner, we have the, the CT pattern, which in this case is probable UIP. We then have the um spirometry trajectory or the force fiber capacity trajectory, uh, and we have very clearly highlighted for us. That the patient has lost 8% over 6 months and you can see that graphically with the graph uh in the middle. Then we have the key information about serology, uh, and we have the key information regarding the treatment that the patient is currently taking. Uh, and then we have that flag in the middle highlighting the fact that the patient has met progressive pulmonary fibrosis criteria. Uh, and Although that does not automatically mean that patients should receive antifibrotic drugs, it is clearly an important trigger for that decision to be considered by the MDT. Uh, and then we can see along the bottom, uh, the, the components that have gone into that flag. Why is it that we've said the patient has met progressive pulmonary fibrosis criteria on this occasion because of worsening symptoms, physiological progression, uh, and radiological progression. So ticking all three boxes, uh, in the PPF criteria. So we have a question for you all. Um, the question is, tracking the symptom flagged PPF criteria met. Margaret's rheumatologist is not on the call. What should happen next? A, proceed with the treatment decision, inform rheumatology afterwards. B, defer all decisions until the rheumatologist can attend. C, start the antifibrotic pathway now and delegate the communication. D, root it through a shared care decision tree with a named owner per step. Or, honestly, there is no defined process for this in my practice. So I, I think The, the key to this, the correct answer to this question is that um we need to recognize who the key participants in the MDT are. Clearly, in a patient with uh an underlying autoimmune disease that is under the care of a rheumatologist, it is important to engage the rheumatologist in the treatment decision. Because there may be need to better treat her underlying autoimmune disease rather than automatically jump to treatment with an anti-fibrotic drug. Uh, and even so, even if the decision is to start an anti-fibrotic drug, it is important that her rheumatologist is a central part of the care team. is at least aware of that. Um, so my personal view would be that we shouldn't be delaying care because the rheumatologist is not attending. Um, but we absolutely need to make sure that her rheumatologist is aware, uh, of the MDT treatment decision so that if he did have any objections, those can be raised early on. Uh, and so probably the best answer is route it through a shared care decision tree with a named owner per step, which is to say you've already got an algorithm in place for your MDT to deal with such situations. So, just to think about how you're doing things, how can we improve care for our patients, um, in your practice right now, is there somebody that's receiving an alert when Margaret's FVC drops 8%? If not, who should that person be? Who then should act on it, um, if it is perhaps the nursing team receiving the alert, what should their step be to make sure that um a physician who can make a prescribing decision has the opportunity to act on it. And then who communicates with the patient, uh, who in this case tells Margaret uh what the decision of the MDT is. Uh, and just again to sort of, um, try and frame this in a way that's relevant to the MDT and I, I think to, to To really put in context the fact that each member of the MDT provides something different, just think about this one question from different perspectives. Which clinical decision support tool do or would you find most useful in this situation? Um, and think about it from a rheumatology, pulmonology, radiology, pathology, or specialist nurse point of view. Um, and it's probably the case that the, the different participants in the MDT are going to have slightly different answers to this question. Um, the rheumatologists and pulmonologists are going to be guiding the care and treatment of the patient. They're going to be supervising the clinical trajectory.